Karyopharm Therapeutics (KPTI) Stock Forecast & Price Target

Karyopharm Therapeutics is a promising commercial-stage pharmaceutical company with its focus on developing novel cancer therapies. Its flagship drug XPOVIO has shown potential in treating a variety of cancers, including endometrial cancer, and has received positive results in a recent study for myelofibrosis. While there are concerns about meeting primary endpoints, the company has secured funding for further research and plans to seek FDA approval for XPOVIO in endometrial cancer. However, investors should be aware of potential risks and challenges in the biotech industry, including the possibility of litigation.

Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on novel cancer therapies, with its primary focus on selinexor, an exportin 1 (XPO1) inhibitor. The company recently faced setbacks with the withdrawal of accelerated approval for selinexor in diffuse large B-cell lymphoma (DLBCL) due to enrollment challenges and the miss on the co-primary endpoint in the Phase III SENTRY trial in myelofibrosis. While the combination of selinexor and ruxolitinib showed a significant benefit in the overall survival (OS) secondary endpoint, there is uncertainty on the likelihood of FDA approval without meeting the mean change in Absolute Total Symptom Score (Abs-TSS) endpoint, which was added at the request of the FDA. The company is heavily dependent on the success of selinexor and has a high level of debt, with only $64 million in cash at the end of 2025. Following the completion of a $30 million private placement, the company is estimated to have pro forma cash of $93 million, which is expected to last until Phase III XPORT-EC-042 data is reported in mid-2026. However, the company still faces risks with its ongoing Phase III XPORT-EC-042 clinical trial